News Releases

Illinois Surgical Quality Improvement Collaborative and Pacira Pharmaceuticals, Inc. Announce Collaboration to Minimize Opioid Exposure for Postsurgical Patients
12/14/17
Pacira Pharmaceuticals to Present at the 2017 BMO Capital Markets Prescriptions for Success Healthcare Conference
12/08/17
Pacira Announces Promotions of Scott Braunstein, MD, to Chief Operating Officer and Richard Scranton, MD, to Chief Scientific Officer
12/07/17
Cancer Treatment Centers of America® Teams with Pacira Pharmaceuticals, Inc. on Innovative Collaboration to Educate Physicians and Patients about Responsible Opioid Use
11/29/17
Pacira Announces FDA Advisory Committee Meeting to Review sNDA for EXPAREL® as a Nerve Block for Regional Analgesia
11/14/17
Pacira Pharmaceuticals to Present at Two November Healthcare Conferences
11/09/17
Pacira Pharmaceuticals, Inc. Reports Third Quarter 2017 Financial Results
11/08/17
Pacira Pharmaceuticals Announces Timing for Third Quarter 2017 Financial Results Webcast and Conference Call
10/31/17
Pacira Pharmaceuticals and TELA Bio Announce Equity Agreement
10/25/17
Pacira Pharmaceuticals Announces FDA Acceptance of sNDA for EXPAREL as a Nerve Block to Produce Regional Analgesia
10/18/17
Pacira Pharmaceuticals CEO to Testify at White House Opioid Crisis Commission Meeting
09/27/17
New Research: Overprescribing of Postsurgical Opioids Poses a Serious Threat to Patients and their Communities; Women Undergoing Surgery are at Greatest Risk
09/26/17
Pacira Pharmaceuticals to Present at the 2017 Cantor Fitzgerald Global Healthcare Conference
09/20/17
Pacira Pharmaceuticals, Aetna, and the American Association of Oral and Maxillofacial Surgeons Join Together in a Program to Reduce Opioid Exposure for Patients Undergoing Wisdom Tooth Extraction
09/13/17
Pacira Pharmaceuticals Announces Multiple EXPAREL Data Presentations at the Upcoming New York School of Regional Anesthesia Annual Fall Symposium
09/06/17
Pacira Pharmaceuticals to Present at the 2017 H.C. Wainwright 19th Annual Global Investment Conference
09/05/17
Pacira Pharmaceuticals to Present at the 2017 Wells Fargo Healthcare Conference
08/31/17
Pacira Pharmaceuticals to Present at the 2017 Wedbush Pacgrow Healthcare Conference
08/09/17
Pacira Pharmaceuticals, Inc. Reports Second Quarter 2017 Financial Results
08/02/17
Pacira Announces Publication of Phase 4 Study of EXPAREL in Patients Undergoing Total Knee Replacement in The Journal of Arthroplasty
07/26/17
Pacira Pharmaceuticals Announces Timing for Second Quarter 2017 Financial Results Webcast and Conference Call
07/25/17
Pacira Announces Topline Phase 3 Results for EXPAREL® as a Single-dose Nerve Block
07/25/17
Pacira Pharmaceuticals Appoints Mark I. Froimson, M.D., to Board of Directors
06/15/17
Pacira Pharmaceuticals to Present at the JMP Securities Life Sciences Conference
06/14/17
Pacira Pharmaceuticals to Present at the Jefferies 2017 Global Healthcare Conference
06/01/17
Pacira Pharmaceuticals Announces Resignation of James Scibetta
05/23/17
Pacira Pharmaceuticals to Present at the Bank of America Merrill Lynch 2017 Healthcare Conference
05/10/17
Pacira Pharmaceuticals, Inc. Reports First Quarter 2017 Financial Results
05/04/17
New Research Shows Vast Majority of Oral Surgery Patients Would Choose Non-opioid Medication to Treat Postsurgical Pain if Given the Option
05/03/17
Pacira Pharmaceuticals Announces Timing for First Quarter 2017 Financial Results Webcast and Conference Call
04/27/17
Pacira Pharmaceuticals, Inc. to Present at the Needham Healthcare Conference
04/03/17
Trinity Health and Pacira Pharmaceuticals Announce Collaboration to Decrease Opioid Use Nationwide
03/16/17
Phase 4 Study Shows EXPAREL® Versus an Active Comparator Significantly Reduces Opioid Consumption and Postsurgical Pain in Patients Undergoing Total Knee Arthroplasty
03/14/17
Pacira Pharmaceuticals, Inc. to Present at the Barclays Global Healthcare Conference
03/13/17
Pacira Pharmaceuticals Announces Pricing of $300 Million Aggregate Principal Amount of 2.375% Convertible Senior Notes due 2022
03/07/17
Pacira Pharmaceuticals Announces Proposed Offering of $300 Million Aggregate Principal Amount of Convertible Senior Notes
03/06/17
Pacira Pharmaceuticals Reports 2016 Financial Results and Provides Business Update
03/01/17
Pacira Pharmaceuticals Announces Timing for 2016 Financial Results Webcast and Conference Call
02/16/17
Pacira Pharmaceuticals, Inc. to Present at the 2017 RBC Capital Markets’ Healthcare Conference
02/15/17
Pacira Pharmaceuticals Announces Collaboration with DePuy Synthes to Support Promotion, Education and Training of EXPAREL® in Orthopedics
01/25/17
Pacira Pharmaceuticals Reports Preliminary 2016 Revenues of $276.4 Million
01/06/17
Pacira Pharmaceuticals, Inc. to Present at the 35th Annual J.P. Morgan Healthcare Conference
01/03/17
Pacira Pharmaceuticals and GeneAlign Announce Partnership to Develop Low-Opioid Pain Management Protocols for Postsurgical Patients at High Risk of Addiction
11/29/16
American College of Surgeons Launches Education Program on Opioids and Surgery: Use, Abuse, and Alternatives
11/22/16
Pacira Pharmaceuticals Unveils Virtual Reality Training Simulation to Enhance Administration Technique Education for EXPAREL® in Total Knee Replacement Surgery
11/11/16
Correction: Pacira Pharmaceuticals, Inc. to Present at Investor Conferences in November
11/10/16
Pacira Pharmaceuticals, Inc. to Present at Investor Conferences in November
11/10/16
Pacira Pharmaceuticals, Inc. Reports Third Quarter 2016 Financial Results
11/02/16
Pacira Pharmaceuticals Continues to Build Out Robust Commercial Leadership Team
10/20/16
Pacira Pharmaceuticals Announces Timing for Third Quarter 2016 Financial Results Webcast and Conference Call
10/17/16
Pacira Pharmaceuticals Announces Official Launch of EXPAREL to the Oral Surgeon Community to Treat Pain Following Oral and Maxillofacial Procedures
09/21/16
Pacira Pharmaceuticals, Inc. to Present at the Morgan Stanley Global Healthcare Conference
09/01/16
Pacira Pharmaceuticals, Inc. to Present at the 2016 Wedbush PacGrow Healthcare Conference
08/09/16
Pacira Pharmaceuticals, Inc. Reports Second Quarter 2016 Financial Results
08/04/16
New Research: Opioid Addiction and Dependence After Surgery is Significantly Higher than Previously Known
08/01/16
Pacira Pharmaceuticals Announces Timing for Second Quarter 2016 Financial Results Webcast and Conference Call
07/15/16
Pacira Pharmaceuticals, Inc. to Present at the Jefferies 2016 Healthcare Conference
05/31/16
Pacira Pharmaceuticals, Inc. to Present at the Bank of America Merrill Lynch 2016 Health Care Conference
05/03/16
Pacira Pharmaceuticals, Inc. Reports First Quarter 2016 Financial Results
05/02/16
Pacira Pharmaceuticals Appoints Charles A. Reinhart III as Chief Financial Officer
04/19/16
Pacira Pharmaceuticals Announces Timing for First Quarter 2016 Financial Results Webcast and Conference Call
04/14/16
Pacira Pharmaceuticals Appoints Robert Weiland as Chief Commercial Officer
04/05/16
Pacira Pharmaceuticals, Inc. to Present at the Barclays Global Healthcare Conference
03/08/16
New Analysis Shows Use of EXPAREL Reduces Length of Hospital Stay and Improves Discharge Status Compared to Standard Analgesic Modality in Total Knee Arthroplasty
03/01/16
Pacira Pharmaceuticals, Inc. Reports 2015 Financial Results
02/25/16
Pacira Pharmaceuticals Announces Timing for 2015 Financial Results Webcast and Conference Call
02/11/16
Pacira Pharmaceuticals Reports Estimated Full-Year 2015 Total Revenue of $249.0 Million
01/07/16
Pacira Pharmaceuticals, Inc. to Present at the 34th Annual J.P. Morgan Healthcare Conference
12/28/15
Pacira Pharmaceuticals Announces Favorable Resolution With U.S. Food and Drug Administration, Which Reaffirms the Broad Indication for EXPAREL®
12/15/15
Pacira Pharmaceuticals, Inc. to Present at the 27th Annual Piper Jaffray Healthcare Conference
11/24/15
New Survey Sheds Light on Prescription Drug Use Among Women After Surgery in the United States
11/17/15
Pacira Pharmaceuticals, Inc. to Present at the Jefferies Autumn 2015 Global Healthcare Conference
11/11/15
New Study Finds Decreased Opioid Use, Hospital Stay and Readmission Rates With EXPAREL Following Knee Replacement Surgery
11/06/15
Pacira Pharmaceuticals, Inc. Reports Third Quarter 2015 Financial Results
10/27/15
Pacira Pharmaceuticals Announces the Promotion of James S. Scibetta to President
10/20/15
Pacira Pharmaceuticals Announces Timing for Third Quarter 2015 Financial Results Webcast and Conference Call
10/13/15
Pacira Pharmaceuticals Seeks Court Injunction to Defend its Rights to Share Information about EXPAREL® Consistent with its FDA-Approved Indication
09/08/15
Pacira Pharmaceuticals Appoints James B. Jones, MD, PharmD, as Senior Vice President and Chief Medical Officer
08/19/15
Pacira Pharmaceuticals, Inc. to Present at Investor Conferences in August
08/03/15
Pacira Pharmaceuticals, Inc. Reports Second Quarter 2015 Financial Results
07/30/15
Animal Health Partner, Aratana Therapeutics, Announces Positive Pivotal Results for Controlling Postsurgical Pain in Dogs
07/15/15
Pacira Pharmaceuticals Announces Timing for Second Quarter 2015 Financial Results Webcast and Conference Call
07/14/15
Pacira Pharmaceuticals Appoints Scott Braunstein, MD, to Oversee Strategy and Corporate Development
07/14/15
Pacira Pharmaceuticals Announces Completion of End-of-Review Process with FDA Regarding EXPAREL sNDA for Nerve Block
05/28/15
Pacira Pharmaceuticals, Inc. to Present at Investor Conferences in June
05/20/15
Pacira Announces New Data Supporting Clinical and Pharmacoeconomic Utility of EXPAREL in Patients Undergoing Various Surgical Procedures
05/19/15
Pacira Pharmaceuticals, Inc. to Present at the Bank of America Merrill Lynch 2015 Health Care Conference
05/07/15
Pacira Pharmaceuticals, Inc. Reports First Quarter EXPAREL Revenues of $56.0 Million and First Quarter 2015 Financial Results
04/30/15
Pacira Receives Subpoena from the U.S. Department of Justice
04/16/15
Pacira Pharmaceuticals Announces Timing for First Quarter 2015 Financial Results Webcast and Conference Call
04/13/15
Pacira Announces New Data on Health Economic Benefits of EXPAREL for Postsurgical Pain Control Following Total Knee Replacement Surgery
04/10/15
Pacira Announces Data Reinforcing Benefits of EXPAREL® for Postsurgical Pain Control Following Total Hip and Knee Replacement Surgery
03/26/15
New Data Demonstrate Reduced Opioid Requirements Following Use of EXPAREL in Hysterectomy and Mastectomy Procedures
03/23/15
Pacira Pharmaceuticals, Inc. to Present at the Barclays Global Healthcare Conference
03/04/15
Pacira Receives Complete Response Letter from FDA for sNDA Seeking Approval of EXPAREL® Use in Nerve Block to Provide Postsurgical Analgesia
03/02/15
Pacira Pharmaceuticals, Inc. Reports 2014 Financial Results
02/24/15
Pacira Pharmaceuticals, Inc. Announces Resolution of Warning Letter with FDA’s Office of Prescription Drug Promotion
02/11/15
Pacira Pharmaceuticals Announces Timing for 2014 Financial Results Webcast and Conference Call
02/10/15
Pacira Pharmaceuticals, Inc. to Host Analyst & Investor Day on Jan. 22 in New York
01/08/15
Pacira Pharmaceuticals, Inc. Reports Estimated Fourth Quarter Total Revenue of $61.8 Million and Estimated Full-Year Total Revenue of $197.7 Million
01/08/15
Pacira Pharmaceuticals Inc. Announces Changes to EXPAREL® Label
12/12/14
Pacira Pharmaceuticals, Inc. to Present at the 26th Annual Piper Jaffray Healthcare Conference
11/25/14
Pacira Pharmaceuticals, Inc. to Present at the Jefferies 2014 Global London Healthcare Conference
11/11/14
Pacira Pharmaceuticals Inc. Announces New Data on the Use of EXPAREL to Treat Postsurgical Pain Following Total Knee Arthroplasty
11/06/14
Pacira Pharmaceuticals, Inc. Reports Third Quarter EXPAREL Revenue of $50.2 Million and Third Quarter 2014 Results
10/30/14
New Study Correlates Use of EXPAREL for Postsurgical Pain Management with Significant Reductions in Opioid Related Adverse Events
10/27/14
Pacira Pharmaceuticals Announces Timing for Third Quarter 2014 Financial Results Webcast and Conference Call
10/15/14
Pacira Pharmaceuticals, Inc. Announces Additional Data Supporting Safety of EXPAREL® in Peripheral Nerve Block
10/13/14
Pacira Pharmaceuticals, Inc. Announces Receipt of FDA Warning Letter
09/25/14
Pacira Pharmaceuticals, Inc. to Present at the Wedbush 2014 Life Sciences Management Access Conference
08/05/14
Pacira Pharmaceuticals, Inc. Reports Second Quarter 2014 Results: EXPAREL Revenue up 31% Over First Quarter
07/31/14
Pacira Pharmaceuticals Announces Timing for Second Quarter 2014 Financial Results Webcast and Conference Call
07/17/14
Pacira Pharmaceuticals, Inc. Announces Publication of Pooled Results from IMPROVE Studies Evaluating Health Economic Benefits of EXPAREL®
06/26/14
Pacira Pharmaceuticals, Inc. to Present at June Investor Conferences
05/27/14
Pacira Pharmaceuticals, Inc. Announces sNDA Submission for EXPAREL Nerve Block Indication
05/07/14
Pacira Pharmaceuticals, Inc. to Present at the Bank of America Merrill Lynch 2014 Health Care Conference
05/05/14
Pacira Pharmaceuticals, Inc. Reports First Quarter EXPAREL Revenue of $34.4 Million and First Quarter 2014 Results
05/01/14
Pacira Pharmaceuticals Announces Timing for First Quarter 2014 Financial Results Webcast and Conference Call
04/17/14
Pacira Pharmaceuticals Announces Grants of Inducement Stock Options Under NASDAQ Listing Rule 5635(c)(4)
04/15/14
Pacira Pharmaceuticals Announces Pricing of Public Offering of Common Stock
04/08/14
Pacira Pharmaceuticals Announces Proposed Public Offering of Common Stock
04/07/14
Pacira Pharmaceuticals Enters into Strategic Co-Production Partnership with Patheon to Create Additional EXPAREL Manufacturing Capacity
04/07/14
EXPAREL Use in Femoral Nerve Block for Total Knee Arthroplasty Further Supported by Additional Data from Phase 3 Pivotal Study, sNDA Submission Planned for Second Quarter 2014
04/04/14
Pacira Pharmaceuticals, Inc. Announces FDA Approval of Additional Manufacturing Suite for EXPAREL
03/31/14
Two New Studies Support Use of EXPAREL for Postsurgical Pain Management Following Total Joint Replacement
03/14/14
Pacira Pharmaceuticals Inc. Appoints Industry Expert Yvonne Greenstreet to its Board of Directors
03/06/14
Pacira Pharmaceuticals Announces EXPAREL® Data Presentations at 2014 Annual Meeting of the American Academy of Orthopedic Surgeons
03/05/14
Pacira Pharmaceuticals, Inc. Announces EXPAREL Phase 3 Clinical Trial in Femoral Nerve Block Meets Primary Efficacy Endpoint
02/27/14
Pacira Pharmaceuticals, Inc. to Present at the Barclays Global Healthcare Conference
02/26/14
Pacira Pharmaceuticals, Inc. Webcast Replay of 2013 Financial Results Conference Call
02/25/14
Pacira Pharmaceuticals, Inc. Reports 2013 Financial Results: Fourth Quarter EXPAREL Revenues Increase 53 Percent Over Third Quarter
02/25/14
Pacira Pharmaceuticals, Inc. Announces Timing for 2013 Financial Results Webcast and Conference Call
02/11/14
Data Update Supports Infiltration with EXPAREL® into the Transversus Abdominis Plane for Postsurgical Pain Management
01/29/14
Phase 4 IMPROVE Publication Finds EXPAREL®- Based Multimodal Analgesia Reduces Opioid Use, Adverse Events and Hospital Stay Following Laparoscopic Surgery
01/07/14
Pacira Pharmaceuticals, Inc. Announces Submission of Prior Approval Supplement for Additional EXPAREL® Manufacturing Suite
12/05/13
Pacira Pharmaceuticals, Inc. to Present at the 25th Annual Piper Jaffray Healthcare Conference
11/25/13
Pacira Pharmaceuticals, Inc. to Present at November Investor Conferences
11/01/13
Pacira Pharmaceuticals, Inc. Reports Third Quarter EXPAREL® Revenue of $20.0 Million and Full Third Quarter 2013 Financial Results
10/31/13
Pacira Pharmaceuticals, Inc. Announces Timing for Third Quarter 2013 Financial Results Webcast and Conference Call
10/17/13
Pacira Pharmaceuticals, Inc. Announces Partnership to Support Uptake of EXPAREL® Among the Orthopedic Marketplace
10/01/13
Study Shows EXPAREL® Provided Improved Pain Control, Shorter Length of Hospital Stay and Substantial Cost Savings Following Total Knee Replacement
09/19/13
Pacira Pharmaceuticals, Inc. Announces Appointment of Life Sciences Industry Veterans Mark Kronenfeld, M.D., and Dennis Winger to its Board of Directors
09/12/13
Pacira Pharmaceuticals, Inc. Reports Second Quarter EXPAREL® Revenue of $15.2 Million and Full Second Quarter 2013 Financial Results
08/06/13
Pacira Pharmaceuticals, Inc. to Present at the Wedbush 2013 Life Sciences Management Access Conference
08/06/13
EXPAREL Phase 3 Clinical Trial in Intercostal Nerve Block Does Not Meet Primary Endpoint
08/01/13
Pacira Pharmaceuticals, Inc. Announces Timing for Second Quarter 2013 Financial Results Webcast and Conference Call
07/30/13
New Study Shows Significant Reduction in Opioids, Length of Hospital Stay and Cost of Care for Patients Receiving EXPAREL® as the Foundation of a Multimodal Postsurgical Pain Regimen
07/18/13
Pacira Pharmaceuticals, Inc. Announces Positive Interim Analysis of EXPAREL in Femoral Nerve Block for Total Knee Arthroplasty
05/29/13
Pacira Pharmaceuticals, Inc. to Present at the Jefferies 2013 Global Healthcare Conference
05/28/13
Pacira Pharmaceuticals, Inc. to Present at the Bank of America Merrill Lynch 2013 Health Care Conference
05/08/13
Pacira Pharmaceuticals, Inc. Reports $10.4 Million in First Quarter EXPAREL Revenue and Full First Quarter 2013 Financial Results
05/08/13
Two New Studies Support Use of EXPAREL via Infiltration Into the Transversus Abdominis Plane for Postsurgical Pain Control
05/06/13
Pacira Pharmaceuticals, Inc. Announces Timing for First Quarter 2013 Financial Results Webcast and Conference Call
05/01/13
New Published Analysis Finds Opioid-Related Adverse Events Increase Hospital Stays, Costs of Care and Risks of Readmission and Mortality
04/25/13
New Data Support the Benefits of EXPAREL for Postsurgical Analgesia Following Aesthetic Plastic Surgery Procedures
04/12/13
Pacira Pharmaceuticals, Inc. to Close The NASDAQ Stock Market on April 8, 2013
04/05/13
Analysis of Postsurgical Pain Management Finds Opioid-Related Adverse Events Drive Longer Hospital Stays, Greater Cost and Higher Likelihood of Readmission
03/27/13
Pacira Pharmaceuticals, Inc. Reports 2012 Financial Results
03/07/13
Pacira Pharmaceuticals, Inc. to Present at the Barclays Global Healthcare Conference
03/06/13
Pacira Pharmaceuticals, Inc. Announces Timing for 2012 Financial Results Webcast and Conference Call
02/28/13
Pacira Pharmaceuticals, Inc. to Present at the Cowen and Company 33rd Annual Health Care Conference
02/25/13
Pacira Pharmaceuticals, Inc. Announces Pricing of $110 Million Private Offering of Convertible Senior Notes
01/17/13
Pacira Pharmaceuticals, Inc. Announces Proposed Offering of $100 Million of Convertible Senior Notes
01/15/13
New Publication Suggests Higher Opioid Use in the Postsurgical Setting May Be Linked to Extended Hospital Stay and Increased Cost of Care
12/18/12
Pacira Pharmaceuticals, Inc. and Aratana Therapeutics Inc. Enter into Global Licensing Agreement for Development and Commercialization of Bupivacaine Liposome Injectable Suspension for Animal Health Indications
12/06/12
New Data Demonstrate Reduction in Opioid Use, Hospital Cost and Length of Stay with EXPAREL as the Foundation of a Multimodal Regimen
11/20/12
Pacira Pharmaceuticals, Inc. to Present at the 24th Annual Piper Jaffray Healthcare Conference
11/20/12
New Data Supporting Use of EXPAREL via Infiltration into the Transversus Abdominis Plane Presented at 11th Annual American Society of Regional Anesthesia and Pain Medicine Meeting
11/13/12
Pacira Pharmaceuticals, Inc. to Present at the Jefferies 2012 Global Healthcare Conference
11/08/12
Pacira Pharmaceuticals, Inc. Reports $4.6 Million in Third Quarter EXPAREL® Revenue and Full Third Quarter 2012 Financial Results
11/01/12
Pacira Pharmaceuticals, Inc. Announces Timing for Third Quarter 2012 Financial Results Webcast and Conference Call
10/25/12
Richard A. Baxter, M.D., Receives OR Excellence Award for Use of EXPAREL®
10/18/12
EXPAREL® as the Foundation of a Multimodal Regimen Achieves Statistical Significance in All Primary Endpoints, Including a 60 Percent Reduction in Length of Hospital Stay
10/08/12
Pacira Pharmaceuticals, Inc. Launches EXPAREL® Pivotal Nerve Block Trial
09/25/12
Pacira Pharmaceuticals, Inc. to Present at the UBS Global Life Sciences Conference
09/12/12
Reduced Pain, Opioid Use, and Opioid-Related Adverse Events in Patients Receiving EXPAREL® Compared With Patients Receiving Bupivacaine HCl as a Component of Multimodal Therapy
09/05/12
Pacira Pharmaceuticals, Inc. Reports $2.3 Million in Second Quarter EXPAREL® Revenue and Full Second Quarter 2012 Financial Results
08/09/12
Pacira Pharmaceuticals, Inc. to Present at the Wedbush PacGrow 2012 Life Sciences Management Access Conference
08/07/12
Pacira Pharmaceuticals, Inc. Announces Timing for Second Quarter 2012 Financial Results Webcast and Conference Call
07/31/12
New Data Quantifying the Effects of Opioid Use on Patient Care and Economic Outcomes Presented at Key Medical Meetings
06/05/12
Pacira Pharmaceuticals, Inc. to Present at the Jefferies 2012 Global Healthcare Conference
05/29/12
Pacira Pharmaceuticals, Inc. to Be Added to NASDAQ Biotechnology Index
05/21/12
Pacira Pharmaceuticals, Inc. to Present at Bank of America Merrill Lynch 2012 Health Care Conference
05/10/12
Pacira Pharmaceuticals, Inc. Reports First Quarter 2012 Financial Results
05/09/12
Pacira Pharmaceuticals, Inc. Completes $27.5 Million Debt Refinancing
05/03/12
Pacira Pharmaceuticals, Inc. Announces Timing for First Quarter 2012 Financial Results Webcast and Conference Call
05/02/12
Pacira Pharmaceuticals, Inc. Announces Full Exercise of Overallotment Option by Underwriters
04/25/12
Pacira Pharmaceuticals, Inc. Prices Public Offering of Common Stock
04/12/12
Pacira Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock
04/11/12
Pacira Pharmaceuticals, Inc. Announces Commercial Availability of EXPAREL®
04/09/12
Pacira Pharmaceuticals, Inc. Reports 2011 Financial Results
03/27/12
Pacira Pharmaceuticals, Inc. Announces Timing for 2011 Financial Results Webcast and Conference Call
03/20/12
Pacira Pharmaceuticals, Inc. to Present at Barclays Capital Global Healthcare Conference
03/07/12
Pacira Pharmaceuticals, Inc. to Participate in RBC Capital Markets Global Healthcare Conference
02/21/12
Pacira Pharmaceuticals, Inc. Provides Update on Commercial Launch and Product Availability Timing for EXPAREL®
01/09/12
Pacira Pharmaceuticals, Inc. Announces Results from EXPAREL™ Pivotal Trial Published in Diseases of the Colon & Rectum
12/19/11
New Data Demonstrating the Impact of Opioid-Related Adverse Events on Total Hospital Cost Presented at American Society of Health-System Pharmacists Meeting
12/05/11
Pacira Pharmaceuticals, Inc. Announces Completion of Follow-on Offering of Common Stock and Exercise of Over-Allotment Option
11/22/11
Pacira Pharmaceuticals, Inc. Announces Pricing of Follow-On Offering
11/16/11
Pacira Pharmaceuticals, Inc. Reports Third Quarter 2011 Financial Results
10/31/11
Pacira Pharmaceuticals, Inc. Announces U.S. FDA Approval of EXPAREL™ For Postsurgical Pain Management
10/31/11
Pacira Pharmaceuticals, Inc. Announces Timing for Third Quarter 2011 Financial Results Webcast and Conference Call
10/24/11
Pacira Pharmaceuticals, Inc. Announces New Data Demonstrating Longer Time to First Opioid Use and Reduction in Opioid-Related Adverse Events With EXPAREL™ Compared to Bupivacaine HCl
10/19/11
Pacira Pharmaceuticals, Inc. Announces Key EXPAREL™ Data to be Presented at American College of Surgeons 97th Annual Clinical Congress
10/18/11
Pacira Pharmaceuticals, Inc. Announces EXPAREL™ Data to Be Presented at Upcoming Medical Meetings
10/11/11
Pacira Pharmaceuticals, Inc. Announces Efficacy and Safety of EXPAREL™ Highlighted at "Hot Topics in Plastic Surgery" Panel at the 2011 Annual Meeting of the American Society of Plastic Surgeons
09/26/11
Pacira Pharmaceuticals, Inc. to Present at UBS Global Life Sciences Conference
09/13/11
Pacira Pharmaceuticals, Inc. Expands EXPAREL™ Commercial Team Infrastructure
09/06/11
Pacira Pharmaceuticals, Inc. to Present at Wedbush Securities 2011 Life Sciences Management Access Conference
08/12/11
Pacira Pharmaceuticals, Inc. Reports Second Quarter 2011 Financial Results
08/11/11
Pacira Pharmaceuticals, Inc. Announces Data Presentations at the 38th Annual Meeting & Exposition of the Controlled Release Society
08/02/11
Pacira Pharmaceuticals, Inc. Announces Timing for Second Quarter 2011 Financial Results Webcast and Conference Call
07/28/11
Pacira Pharmaceuticals, Inc. Announces Inclusion in Russell 3000 Index
06/27/11
Pacira Pharmaceuticals, Inc. Announces FDA Extension of EXPAREL™ PDUFA Target Date by Three Months
06/14/11
Pacira Pharmaceuticals, Inc. Appoints Two Life Sciences Industry Veterans to Its Board of Directors
06/02/11
Pacira Pharmaceuticals, Inc. to Present at UBS Global Specialty Pharmaceuticals Conference
05/24/11
Pacira Pharmaceuticals, Inc. Announces EXPAREL™ Data Presentations at the International Anesthesia Research Society 2011 Annual Meeting
05/23/11
Pacira Pharmaceuticals, Inc. Announces Phase 3 EXPAREL™ Data Presentation at the American Society of Colon and Rectal Surgeons 2011 Annual Meeting
05/16/11
Pacira Pharmaceuticals, Inc. Reports First Quarter 2011 Financial Results
05/11/11
Pacira Pharmaceuticals, Inc. Announces EXPAREL™ Data Presentations
05/05/11
Pacira Pharmaceuticals, Inc. Announces Timing for First Quarter 2011 Financial Results Webcast and Conference Call
05/04/11
Pacira Pharmaceuticals to Present at BioCentury Future Leaders in the Biotech Industry Conference
04/08/11
Pacira Pharmaceuticals Reports Fourth Quarter and 2010 Financial Results
03/31/11
Pacira Pharmaceuticals Announces Timing for 2010 Financial Results, Webcast and Conference Call
03/24/11
Pacira Pharmaceuticals to Present at the Barclays Capital 2011 Global Healthcare Conference
03/08/11
Pacira Pharmaceuticals' EXPAREL™ Data to be Featured at 2011 ASCPT 112th Annual Meeting
03/02/11
Pacira Pharmaceuticals Highlights Additional Safety Data on EXPAREL™ for Postsurgical Pain Relief at 2011 American Academy of Orthopaedic Surgeons Annual Meeting
02/15/11
Pacira Pharmaceuticals, Inc. Announces Pricing of Its Initial Public Offering
02/03/11
Pacira Pharmaceuticals Presents New Data from EXPAREL Phase 3 Study at Orthopaedic Research Society’s 57th Annual Meeting
01/13/11
Pacira Pharmaceuticals Announces FDA Acceptance of EXPAREL™ New Drug Application for Pain Management
12/14/10
Pacira Announces Results of Another Positive Phase III Trial in Post Operative Pain
12/01/09
Pacira's Phase III Study of EXPAREL™ Meets Primary Pain Relief Endpoint
10/20/09
Phase III Studies of EXPAREL™ (DepoBupivacaine) from Pacira Complete Enrollment
01/06/09
Positive Phase II Study of Pacira’s EXPAREL™ (DepoBupivacaine) in Hernia Repair Presented at the Postgraduate Assembly in Anesthesiology (PGA)
12/14/08
Positive Phase II Study of Pacira's EXPAREL™ (DepoBupivacaine) in Total Knee Arthroplasty Presented at International College of Surgeons World Congress
12/06/08
Pacira Pharmaceuticals, Inc. Adds Experienced Physician Dr. David St. Peter to Leadership Team
10/02/08
Pacira Pharmaceuticals, Inc. Adds Experienced CFO James S. Scibetta to Leadership of the Organization
08/06/08
Pacira Pharmaceuticals, Inc. Adds Board Member and Key Senior Management
07/08/08
Pacira Pharmaceuticals, Inc. Expands Development Collaborations for Depofoam®
04/15/08
Pacira Pharmaceuticals Names David M. Stack CEO and President
12/17/07
Orphan Australia Pty Ltd receives registration approval for the new dose form DepoDur®, Pacira’s modified release injection of morphine sulfate
10/22/07
Flynn Pharma Acquires Rights from Pacira Pharmaceuticals to DepoDur®
09/27/07
EKR Therapeutics Achieves Key Growth Milestone with the Acquisition of Rights from Pacira Pharmaceuticals to DepoDur®
08/15/07
SkyePharma, Inc., Now a Private Pharmaceutical Company, Announces Name Change to Pacira Pharmaceuticals, Inc.
06/22/07